Patents by Inventor Roine Ingemar OLSSON

Roine Ingemar OLSSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 11453644
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: September 27, 2022
    Assignee: AstraZeneca, AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • 2,3-DIHYDROISOINDOLE-1-CARBOXAMIDES USEFUL AS ROR-GAMMA MODULATORS
    Publication number: 20210380533
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Application
    Filed: May 7, 2021
    Publication date: December 9, 2021
    Inventors: Sarah LEVER, Frank NARJES, Roine Ingemar OLSSON, Stefan VON BERG
  • 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
    Patent number: 11034654
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: June 15, 2021
    Assignee: AstraZeneca AB
    Inventors: Sarah Lever, Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg
  • Compounds
    Patent number: 10988445
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: April 27, 2021
    Assignee: AstraZeneca AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • NOVEL COMPOUNDS
    Publication number: 20200181084
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Application
    Filed: November 25, 2019
    Publication date: June 11, 2020
    Applicant: AstraZeneca AB
    Inventors: Frank NARJES, Roine Ingemar OLSSON, Stefan VON BERG, Sarah LEVER
  • NOVEL COMPOUNDS
    Publication number: 20200115338
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Application
    Filed: June 13, 2018
    Publication date: April 16, 2020
    Inventors: Sarah LEVER, Frank NARJES, Roine Ingemar OLSSON, Stefan VON BERG
  • Compounds
    Patent number: 10526286
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: January 7, 2020
    Assignee: AstraZeneca AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • NOVEL COMPOUNDS
    Publication number: 20190084934
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Application
    Filed: June 4, 2018
    Publication date: March 21, 2019
    Applicant: AstraZeneca AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • Compounds
    Patent number: 10011566
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: July 3, 2018
    Assignee: AstraZeneca AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • Novel Compounds
    Publication number: 20170166527
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Application
    Filed: December 14, 2016
    Publication date: June 15, 2017
    Applicant: AstraZeneca AB
    Inventors: Frank NARJES, Roine Ingemar OLSSON, Stefan VON BERG, Sarah LEVER